PACIRA BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 27.77K shares.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 182.00 shares.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 29.80K shares.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 30.53K shares.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 62.68K shares, a 90.91% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 689.46K shares, a 5.83% decline from fiscal 2021.
- PACIRA BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2021 was 732.12K shares, a 48.74% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 27.77K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | |
| 2026-03-31 | 182.00 shares 10-Q · filed 2026-04-30 | |
| 2025-12-31 | 29.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 30.53K shares 10-K · filed 2026-02-26 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 62.68K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 784.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 84.20K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-06-30 | 49.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 120.95K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2023-03-31 | 12.06K shares 10-Q · filed 2023-05-03 | 378.33K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | 21.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 689.46K shares 10-K · filed 2024-02-29 |
| 2022-09-30 | 37.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 847.03K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | 307.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | 883.16K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | 323.20K shares 10-Q · filed 2022-05-04 | 738.06K shares derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | 179.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 732.12K shares 10-K · filed 2024-02-29 |
| 2021-09-30 | 73.66K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 851.37K shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | 162.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | 1.48M shares derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | 317.26K shares 10-Q · filed 2021-05-04 | |
| 2020-12-31 | 298.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 1.43M shares 10-K · filed 2023-02-28 |
| 2020-09-30 | 702.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |